CTLA4 and neoplasm: According to literature report, anti-CTLA-4 antibody overcomes a block in essential costimulatory signals (i.e., CTLA-4 and CD28 competes for the same ligands CD80 and CD86; CTLA-4 has a higher affinity than CD28) that are required for activation of both naive T cells and resting clones, whereas PD-1/PD-L1 blockade seems to remove a barrier and enable T cell effector function at the tumor site [116,117].